ID   FR-M-204
AC   CVCL_C548
DR   cancercelllines; CVCL_C548
DR   Cosmic; 2163850
DR   ESTDAB; ESTDAB-164
DR   Wikidata; Q54835148
RX   PubMed=23851445;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val218Gly (c.653T>G); ClinVar=VCV000528249; Zygosity=Unspecified (PubMed=23851445).
ST   Source(s): ESTDAB=ESTDAB-164
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9,11
ST   D3S1358: 14,16
ST   D5S818: 12
ST   D7S820: 11
ST   FGA: 19,22
ST   TH01: 7,9.3
ST   TPOX: 8,10
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 14
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//